Miami-based medical technology startup Swift Sync has secured another investment from Boca Raton-based New World Angels (NWA), following a major regulatory milestone that brings its innovative cardiac pacing technology one step closer to the U.S. healthcare market.
The latest investment follows the U.S. Food and Drug Administration's July 30, 2026, clearance of Swift Sync's Sync AV II Temporary Pacing Catheter, a medical device designed to improve temporary cardiac pacing by synchronizing the heart's upper and lower chambers through a single catheter.
New World Angels has now invested approximately $1.4 million in Swift Sync across multiple funding rounds, beginning with its leadership of the company's Series A financing in 2021. Swift Sync has raised approximately $5 million in total funding.
The development marks an important step for a Florida-grown medical technology company and highlights the role of sustained early-stage investment in bringing complex healthcare innovations from research laboratories to commercial markets.
From University Research to FDA Clearance
Founded by Dr. Eduardo de Marchena and Dr. Christian Marin y Kall, Swift Sync emerged from research at the University of Miami with a mission to advance temporary cardiac pacing technology.
Traditional temporary pacing systems frequently stimulate only the heart's right ventricle, which can disrupt the natural coordination between the upper and lower chambers. This lack of synchronization can negatively affect cardiac performance in certain patients.
Swift Sync's Sync AV II Temporary Pacing Catheter addresses this challenge by enabling atrioventricular synchronous pacing through a single catheter, helping maintain coordination between the heart's chambers. The device is intended for temporary intracardiac pacing for up to three days, according to its FDA-cleared indications for use.
Before receiving regulatory clearance, Swift Sync completed its 30-patient EASY II clinical study in Paraguay. All 30 patients were successfully implanted with the device, and the study met its primary efficacy endpoint without reporting serious procedure-related complications.
The findings were published in the peer-reviewed journal Pacing and Clinical Electrophysiology. The study reported successful catheter implantation in all 30 patients, achievement of its primary efficacy endpoint and no serious procedure-related complications, providing early clinical evidence supporting the device's performance and safety.
The FDA's 510(k) clearance, granted July 30, represents a significant regulatory achievement and allows the company to move toward commercial introduction in the United States.
New World Angels' Long-Term Commitment to Swift Sync
For New World Angels, the latest investment represents more than another portfolio transaction. It reflects a relationship spanning several years of product development, clinical validation and regulatory review.
The Florida-based angel investor partnership first backed Swift Sync in 2021, leading the company's $3.5 million Series A financing with a $1.2 million investment. Since then, NWA has continued supporting the company as it navigated the lengthy and capital-intensive process of bringing a new medical device toward market.
"Throughout our history with Swift Sync - including backing the company during multiple rounds of funding - this clearance is a milestone we've been working toward alongside Christian and the team," said Steve O'Hara, chairman of New World Angels and co-chair of its Healthcare Ventures Group. "This latest investment from NWA reflects our support and confidence in what comes next for Swift Sync's innovative technology."
For Swift Sync's leadership, the milestone represents years of collaboration among researchers, clinicians, engineers and investors, with Florida serving as the foundation for the company's development. The amount of the latest individual investment was not disclosed.
A Growing Statewide Investment Network
The investment also comes during a period of expansion for New World Angels. As previously reported, Miami Angels merged into New World Angels in March 2026, bringing together two established South Florida angel investment communities under a unified platform.
The merger expanded New World Angels' investor base, industry expertise and geographic reach, while increasing its capacity to participate in larger funding rounds and support portfolio companies through follow-on investments.
In VTC's earlier coverage, NWA Managing Director Jessica Miley emphasized that the expanded organization would maintain its disciplined early-stage investment approach while increasing its ability to deploy capital and access promising companies across Florida.
The continued backing of Swift Sync illustrates the importance of that investment model, particularly for medical technology startups that often require multiple funding rounds before reaching commercialization. Unlike software companies that can bring products to market relatively quickly, medical device startups frequently face years of research, product development, clinical testing and regulatory review before generating meaningful commercial revenue.
For investors, that creates longer development timelines and additional risk. For founders, it makes access to patient capital and experienced investment partners particularly valuable.
What's Next for Swift Sync?
With FDA clearance secured, Swift Sync is preparing for the next stage of its development: bringing the Sync AV II Temporary Pacing Catheter to market.
That transition introduces a different set of challenges, including manufacturing, distribution, hospital adoption and broader commercialization. While regulatory clearance establishes a pathway to the U.S. market, the company's long-term commercial success will depend on its ability to translate clinical results into healthcare provider adoption and sustainable sales.
For Swift Sync's leadership, reaching this milestone represents years of collaboration among researchers, clinicians, engineers and investors, with Florida serving as the foundation for the company's development.
“Swift Sync was born and built in Florida, from the first prototype through FDA clearance. That path has taken years of work from a broad array of team members, including those at New World Angels,” said Dr. Christian Marin y Kall, co-founder and chief operating officer of Swift Sync. “As we take the next step towards market introduction, we're glad to continue to count New World Angels among our key partners.”
Specific details regarding the company's commercial launch timeline, distribution strategy and potential future financing have not yet been announced.
For New World Angels, the investment reinforces a strategy of supporting promising Florida companies beyond their initial funding rounds. For South Florida's innovation ecosystem, Swift Sync represents another example of university-originated research progressing into a potentially commercial medical technology.
And for a region increasingly recognized for its growing network of entrepreneurs, investors and research institutions, the company's journey demonstrates how locally developed innovation, supported by long-term capital, can advance toward the national healthcare market.
Miami-based medtech startup Swift Sync has secured additional investment from New World Angels following FDA clearance of its innovative cardiac pacing catheter. With approximately $5 million raised, the University of Miami-born company is advancing toward commercialization, highlighting the strength of South Florida's growing healthcare innovation and investment ecosystem.